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Background: Elevated resting heart rate is associated with worse outcomes in chronic heart failure (HF) but little
is known about its prognostic impact in acute setting. The main aim of the present study was to examine the
relationship between resting heart rate obtained 24–36 h after admission for acute non-arrhythmic HF and in-
hospital mortality.
Methods and results:We examined the association of heart rate with in-hospital mortality in a cohort of 712 pa-
tients admitted for acute HF. None of the patients had signiﬁcant arrhythmias, required invasive ventilation, or
presented with acute coronary syndrome or primary valvular disease. Forty patients (5.6%) died during the
hospital stay. Those patients were signiﬁcantly older (78 ± 9 vs. 72 ± 12 years; p = 0.0021), had higher heart
rate (92 ± 22 vs. 78 ± 18 bpm; p b 0.0001), NT pro-BNP (p = 0.0005), creatinine (p = 0.023), were often
diabetics (p = 0.026) and had lower systolic and diastolic blood pressures (p b 0.05). There was a signiﬁcant
graded relationship between the increase inmortality rate and tertile of heart rate (p b 0.01).Withmultivariable
analysis, age (p = 0.037), heart rate (p b 0.0001), diastolic blood pressure (p b 0.001), prior ischemic heart
disease (p = 0.02) and creatinine (p = 0.019) emerged as independent predictors of in-hospital mortality.
After adjusting for predictors of poor prognosis, patients in the highest heart rate tertile had worst outcomes
when compared with those in the lowest heart rate group (p = 0.007).
Conclusions:Higher heart rate 24–36 h after admission for acute non-arrhythmic HF is associated with increased
risk of in-hospital mortality. Early targeting of elevated heart rate might represent a complementary therapeutic
challenge.© 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Acute heart failure (HF) is a common and growingmedical problem
associated with major morbidity and mortality [1]. Options for the
management of these patients remain limited with high in-hospital
mortality rates. Accurate individual risk stratiﬁcation can thus help
physicians choose the intensity of care needed and promote tailored
medical decision-making [2]. Previous studies have identiﬁed a number
of variables that are associated with increased morbidity and mortality
in HF [3,4]. However, most of these studies examined heterogeneous
cohorts of patients with severe illness conditions such as cardiogenic
shocks, acute coronary syndromes, and HF-related arrhythmias. Elevat-
ed resting heart rate has been recently recognized as a strong indepen-
dent predictor of reduced life expectancy in patients with chronic HF
and reduced left ventricular ejection fraction. Being also related to
sympathetic overactivity, atherosclerosis and plaque vulnerability,University Hospital, Université
tti).
eliability and freedom from bias
.resting heart rate mediated arterial stress has progressively become a
fascinating medical target per se, which has been further stressed by
the recent results of the Systolic Heart failure treatment with the If in-
hibitor ivabradine Trial (SHIFT) [5]. In acute non-arrhythmic HF, little
is known about the impact of elevatedheart rate on in-hospital outcome
[6]. However, higher heart rate at hospital discharge in patients with HF
has been associated with greater risk of all-cause and cardiovascular
mortality up to 1-year follow-up, and elevated risk of 30-day readmis-
sion for HF and cardiovascular disease [7]. The main aim of the present
study was to examine the relationship between resting heart rate ob-
tained in survivors 24–36 h after admission for acute non-arrhythmic
HF and in-hospital mortality.
2. Methods
2.1. Patients
The present study collected detailed hospitalization data from computerized medical
records of patients presenting with acute HF at CHU of Liège, Belgium, between 2010 and
2012. Patients (n = 1611) were eligible for the ﬁrst round of selection if they were
N18 years of age, had a suspected diagnosis of HF and were alive 24–36 h after admission.
After a second round of selection, 899 patients with ≥1 following criteria were further
disqualiﬁed: respiratory support, cardiogenic shock, acute coronary syndrome, inotropic
support, primary valvular heart disease, permanent pacemaker pacing, atrial ﬁbrillation,
Table 1
Demographic, clinical and biologic data.
Variables 1st tertile 2nd tertile 3rd tertile p
Age, years 72 ± 12 72 ± 12 72 ± 13 0.94
Systolic blood pressure, mm Hg 121 ± 28 121 ± 22 124 ± 23 0.47
Diastolic blood pressure, mm Hg 66 ± 11 67 ± 13 71 ± 15 0.0023
Left ventricular ejection fraction, % 46 ± 17 44 ± 16 44 ± 15 0.24
Left ventricular ejection fraction b 45%, n (%) 56 (33) 158 (43) 79 (45) 0.37
Medical history
Diabetes, n (%) 25 (15) 60 (16) 47 (27) 0.029
Ischemic heart disease, n (%) 82 (48) 158 (43) 58 (33) 0.013
Medications
ACE inhibitor, n (%) 78 (46) 126 (35) 49 (28) 0.0021
Beta-blocker, n (%) 85 (50) 138 (37) 55 (31) 0.0015
Laboratory ﬁndings
NT-proBNP, pg/mL 9306 ± 9063 9735 ± 15133 9562 ± 10179 0.99
Creatinine, mg/dL 17.3 ± 15.5 14 ± 10 13 ± 8 0.003
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stage renal failure requiring dialysis, and cancer. A total of 712 patients in sinus rhythm at
24–36 h after admission were qualiﬁed for ﬁnal inclusion in the study. The following
clinical data were abstracted from hospital records: demographic information, the use of
beta-blockers or angiotensin-converting enzyme (ACE) inhibitor at admission, medical
history, prior myocardial infarction, prior hear failure hospitalization, laboratory ﬁndings
(hemoglobin, sodium, creatinine, NT-proBNP), heart rate and blood pressure at 24–36 h
after admission, left ventricular ejection fraction, and in-hospital mortality. The study pro-
tocol conforms to the ethical guidelines of the 1975Declaration of Helsinki as reﬂected in a
priori approval by the institution's human research committee.
2.2. Deﬁnitions
Hospital heart rate was deﬁned as the ﬁrst reported heart rate in the medical record
obtained at 24–36 h after admission. It derived from either electrocardiogram or cardiac
monitoring. Hospital heart rates were categorized into tertiles. The diagnosis of HF was
based upon the following conditions to be satisﬁed: symptoms typical of HF, signs of HF,
either reduced left ventricular ejection fraction or diastolic dysfunction with structural
heart disease and increasedNT-proBNP (N300 pg/mL) [8]. Hemoglobin, sodium and creat-
inine levels were obtained the day of heart rate evaluation. Left ventricular ejection
fraction was also extracted from the closest echocardiography report to hospital heart
rate assessment. Patients were classiﬁed as newly hospitalized if no history of HF was re-
ported in the medical record. The primary end-point of the study was the in-hospital
death, deﬁned as any cause of death occurring during the hospitalization.
2.3. Statistical methods
Data are reported as mean ± standard deviation for continuous variables or percent-
ages of patients for categorical variables. Heart rateswere tested for distribution normality
with the Kolmogorov–Smirnov test. Group comparisons for categorical variables wereTable 2
Univariable analysis: predictors of in-hospital mortality.
Variables Whole cohort
(n = 712)
Age, years 72 ± 12
Male gender, n (%) 425 (59)
Heart rate, bpm 79 ± 18
Systolic blood pressure, mm Hg 121 ± 24
Diastolic blood pressure, mm Hg 68 ± 13
Left ventricular ejection fraction, % 44 ± 16
Left ventricular ejection fraction b 45%, n (%) 293 (41)
Medical history
Hypertension, n (%) 331 (46)
Diabetes, n (%) 132 (19)
COPD, n (%) 177 (25)
Ischemic heart disease, n (%) 298 (42)
Prior HF, n (%) 311 (44)
Medications
ACE inhibitor, n (%) 253 (36)
Beta-blocker, n (%) 278 (39)
Laboratory ﬁndings
Hemoglobin, g/L 12 ± 2
NT-proBNP, pg/mL 9615 ± 12872
Creatinine, mg/dL 14 ± 11
Sodium, mmol/L 140.7 ± 4.4obtained with chi-square test and for continuous variables with t-test or 1-way analysis
of variance with a Tukey post-hoc test. A logistic model was applied to identify signiﬁcant
predictors of in-hospital mortality. In order to avoid overﬁtting the multivariable model,
we have only included signiﬁcant univariable parameters. Values of p b 0.05 were consid-
ered signiﬁcant. All statistical analyses were performed with STATISTICA version 7
(StatSoft Inc, Tulsa, OK). Sensitivity and speciﬁcity for prediction of in-hospital mortality
were determined for various cut-off values of hospital heart rate level using receiver oper-
ating characteristic (ROC) curves. The authors had full access to and take full responsibility
for the integrity of the data. All authors have read and agree to the manuscript as written.
3. Results
3.1. Patients' characteristics
Among the 712 patients included (72 ± 12 years, 60% males), 46%
had hypertension, 19% were diabetics, 18% previously experienced
myocardial infarction, 42% had ischemic heart disease and 44% had
prior HF diagnosis (Table 1). Left ventricular systolic dysfunction (ejec-
tion fraction b 45%) was identiﬁed in 293 (41%) patients. ACE-inhibitor
and beta-blocker were taken at the time of admission by 253 and 278
patients, respectively.
3.2. Heart rate categories
Mean heart rate was 78.9 ± 18.2 bpm (median 76 bpm, range: 43–
150 bpm, Table 2). According to heart rate tertile (1st tertile: 43–Survivors
(n = 672, 94%)
Death
(n = 40, 5.6%)
p
72 ± 12 78 ± 9 0.0021
396 (58) 29 (72) 0.08
78 ± 18 92 ± 22 b0.0001
122 ± 24 113 ± 30 0.046
68 ± 13 58 ± 16 0.0002
44 ± 16 46 ± 15 0.46
276 (41) 16 (40) 0.64
314 (47) 17 (43) 0.17
118 (18) 14 (35) 0.026
166 (25) 11 (28) 0.96
274 (41) 24 (60) 0.017
287 (43) 24 (60) 0.032
245 (36) 8 (20) 0.035
269 (40) 9 (22.5) 0.027
12 ± 2 12 ± 2 0.63
8488 ± 10660 24692 ± 26433 0.0005
14 ± 10 18.5 ± 18 0.023
141 ± 4.2 140 ± 6.3 0.71
Fig. 1. Impact of tertile of 24–36 h heart rate on in-hospital mortality in both univariable
(Panel A) and multivariable (Panel B) analyses.
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with a higher heart rate were often diabetics and more likely to have
suffered from previous ischemic heart disease. A higher resting heart
rate was also associated with higher diastolic blood pressure. The
proportion of patients treated with a betablocker or ACE-inhibitor de-
creased as heart rate increased, whereas the renal function was better
in the 3rd heart rate tertile.
3.3. In-hospital outcome
Forty patients (5.6%) died during the hospital stay. There was a sig-
niﬁcant graded relationship between increase in mortality rate andTable 3
Multivariable analysis: predictors of in-hospital mortality.
Variables Odds-ratio 95% conﬁdence
Interval
p
Age, per year 1.049 1.002–1.099 0.040
Diastolic blood pressure, per mm Hg 0.940 0.910–.972 b0.0001
Ischemic heart disease 2.899 1.125–7.471 0.028
Beta-blocker 0.313 0.012–8.079 0.484
ACE inhibitor 1.130 0.045–28.480 0.941
Creatinine, per mg/mL 1.040 1.011–1.071 0.007
Heart rate, per bpm 1.041 1.021–1.062 b0.0001tertile of heart rate (1st tertile: 2.6%; 2nd tertile: 4.1% and 3rd tertile:
10%, p b 0.01). Using ROC curves analysis, the best cut-off value of
hospital heart rate to predict in-hospital mortality was 91 bpm (sensi-
tivity = 55%; speciﬁcity = 81%; area under the curve = 0.7). Patients
in tertile 3 of heart rate had a 4.19-fold increase in risk of in-hospital
death, as compared to those in 1st tertile (Fig. 1, Panel A).
3.4. Predictors of in-hospital mortality
The comparison between patients with in-hospital death and survi-
vors regarding demographic, clinical and biologic data is reported in
Table 2. In-hospital survivors were signiﬁcantly younger and often of
male gender. Conversely, in-hospital death patients' were more
frequently with diabetes, lower systolic and diastolic blood pressures,
and higher heart rate at 24–36 h after admission. Of note, there was
no signiﬁcant difference between in-hospital death and survivors
regarding chronic obstructive disease, prior myocardial infarction and
heart failure episodes. Patients taking an angiotensin-converting
enzyme inhibitor or beta-blocker at the time of admission faced lower
risk of in-hospital mortality. Interestingly, patients were also at higher
risk of death if they had higher NT-proBNP release and creatinine levels.
With multivariable analysis, age (OR = 1.05; p = 0.037), heart rate
(OR=1.04; p b 0.0001), diastolic blood pressure (OR=0.94; p b 0.001)
prior ischemic heart disease (OR=4.2; p=0.02) and creatinine (OR=
1.03; p = 0.019) emerged as independent predictors of in-hospital
mortality (Table 3). Similarly, after adjusting for predictors of poorFig. 2. Impact of categories of 24–36 h heart rate on in-hospital mortality in both
univariable (Panel A) and multivariable (Panel B) analyses.
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tertile had worse outcomes when compared with those in the lowest
heart rate group (Fig. 1, Panel B).
As compared to patients with a heart rate ≤80 bpm, those with a
heart rate N91 bpm were at the highest risk of in-hospital death.
Univariately, heart rate N91 bpmwas associatedwith 5.39-fold increase
in risk of death (Fig. 2, Panel A). Using multivariable analysis, heart rate
N91 bpmwas identiﬁed as independently associatedwith increased risk
of in-hospital death (OR = 7.29, p b 0.0001, Fig. 2, Panel B).
4. Discussion
Risk of in-hospital mortality for patients hospitalized with acute
non-arrhythmic HF is high (5.6%) and varied signiﬁcantly based upon
24–36 h heart rate levels. Heart rate levels provide risk prediction inde-
pendently of numerous other clinical (older age, lower blood pressure,
prior history of ischemic heart disease) and laboratory (increased
serum creatinine) variables previously demonstrated to be predictive
of in-hospital outcomes [9]. Our ﬁndings are the ﬁrst to demonstrate
that including heart rate evaluation early after admission for acute
non-arrhythmic HF in patients with non-severely ill conditions (i.e. car-
diogenic shock) provides incremental prognostic information for in-
hospital mortality.
4.1. Heart rate and outcome in HF
Previous studies have shown that elevated heart rate levels predict
prognosis in patients presenting with HF [6,10]. Autonomic imbalance
resulting from sympathetic overactivity and parasympathetic with-
drawal is likely to be the underlying mechanism of increased heart
rate in HF [11]. Several pathophysiologic mechanisms, including
increased myocardial oxygen consumption, reduced diastolic ﬁlling
times, compromised coronary perfusion with induction of myocardial
ischemia, and precipitation of rhythmdisturbances have been proposed
to explain the association between higher heart rate and worse
outcomes in patients with HF [5,12–15].
While the present study was generally consistent with previous re-
ports, our data exclusively focused on acute HF patients surviving 24–
36 h after admissionwhowere not in cardiogenic shock, acute coronary
syndrome, arrhythmias, or respiratory support. As a result, our mean
hospital heart rate (79 ± 18 bpm) was lower than the mean heart
rate at admission in the OPTIMIZE-HF (87± 22 bpm) [6], the Aronson's
report (84 ± 16 bpm) [16], the ESC HF pilot study (88 ± 24 bpm) [17],
and the IN-HF Italian registry (93 ± 26 bpm) [18]. The in-hospital mor-
tality rate varied in these studies from 3.8% to 6.4%, which intriguingly
remains close to ours.
For the ﬁrst time, we reported the relationship between 24–36 h
heart rate categories and hospital outcome. Speciﬁcally, heart rates ex-
ceeding 91 bpm were associated with higher in-hospital mortality
while lower thresholds portended better hospital prognosis. Several
factors were associated with higher hospital heart rate. Some of them
were paradoxically predictors of in-hospital survival (i.e. lower frequen-
cy of prior ischemic heart disease, higher diastolic blood pressure, and
lower serum creatinine level), whereas others were markers of in-
hospital mortality (i.e. diabetes, lower rate of beta-blockers and ACE
inhibitors use). Conversely, there was no interaction between resting
heart rate and left ventricular ejection fraction, indicating that the
value of elevated heart rate in predicting in-hospitalmortalitywas inde-
pendent of left ventricular systolic function. In-hospital mortality was
thus similar in patients with reduced or preserved LV ejection function.
Similar to someprior reports, patients with a de novoHF hospitalization
tended to be at lower risk for in-hospital mortality [19]. Of particular
interest, the use of beta-blockers or ACE inhibitors at the time of admis-
sion predicted improved in-hospital survival in the lower heart rate
groups. These data underline again the importance of heart rate control
in HF. In patients surviving the acute HF phase, higher heart rate atdischarge but not at admission emerged as a potent predictor of 30-
daymortality in the study ofHabal et al. Interestingly, this trend reached
signiﬁcance at heart rates above 90 bpm, a cut-off close to ours [7].
However, the impact of heart rate at admission on in-hospital mortality
was not examined in that study.Whether the hospital heart rate is rath-
er a predictor of in-hospitalmortality and the discharge heart rate a pre-
dictor of short-term outcome needs to be addressed in speciﬁc studies.
4.2. Clinical implications
The continued high mortality rate for patients hospitalized with
acute HF provides a compelling indication for accurate risk stratiﬁcation
to potentially improve individual management and hospital outcome.
Recent studies have suggested heart rate reduction per se as a mecha-
nism responsible for improvement of clinical outcomes in patients
with chronic HF [5]. Although cautious interpretation is required, the
results of the present study might support the concept that heart rate
reduction might also represent a speciﬁc therapeutic target per se
soon after hospitalization for acute HF, especially in patients with
prior ischemic heart disease [20]. In our study, one third of patients in
the higher heart rate quartile had prior ischemic heart disease, a popu-
lation inwhom rigorous heart rate control improves outcome. Either re-
duction of adrenergic tone by beta-blockers or pure heart rate-lowering
by If current inhibitor ivabradine, which selectively blocks the sinus
node to lower heart rate, might be targeted. In practice, beta-blockers
remain the ﬁrst-line therapy in HF patients and should be started as
soon as possible after stabilization and if blood pressure and heart rate
permit [8]. Ivabradine represents a second line treatment if heart rate
remains N70 bpmdespite beta-blockers, butmight represent a potential
alternative approach in the early stage of HF hospitalization since it
affects less the hemodynamic status.
4.3. Limitations
This study has a number of limitations. Our results do not pertain to
all patients presenting with acute HF (i.e. cardiogenic shock). Only
patients surviving at 24–48 h after admissionwere evaluated,which ex-
cluded severely ill patients presentingwith an early death. Earlymortal-
ity is known to occur in very frail patients with several comorbidities,
which represent signiﬁcant confounding ﬁndings. Therefore, measuring
heart rate at admission does not likely provide ameaningful assessment
of the independent prognostic value of this parameter. In our study, the
heart rate at admission was not evaluated as well as the time course of
changes in heart rate during the hospital stay. In fact, the scope of the
present study was to evaluate in-hospital mortality in relation with
heart rate obtained in survivors 24–36 h after admission for acute HF.
However, it should be acknowledged that although the heart rate was
measured late after admission, all survivors were not necessarily hemo-
dynamically stabilized. All this suggests that persistent elevated heart
rate at 24–36 h likely represents an independent critical prognostic
marker in non-completely stabilized patients. Therefore, the prognostic
impact of elevated heart rate at 24–36 hmay also reﬂect persisting pre-
carious hemodynamic status. Furthermore, the optimal timing for the
measurement of heart rate remains to be addressed. This is particularly
true at admission.Whether the clinical meaning of heart rate measured
at hospital arrival in the emergency department, or in the intensive care,
or before or after treatment initiation is similar remains unknown. The
advantage of measuring heart rate at a ﬁxed period after admission
(24–36 h) allows standardization of data collection mode, which is
more reliable for comparative studies. The exclusion of patients with
atrial ﬁbrillation is actually the strength of this analysis on HR and out-
come. The inﬂuence of any antiarrhythmic drugswas not evaluated; the
use of them did not represent an exclusion criterion. Before 2012, NT-
proBNP was not routinely measured in our hospital, resulting in small
number of patients with these data available. In this regard,we have de-
cided not to include NT-proBNP in the mutltivariable model in order to
430 P. Lancellotti et al. / International Journal of Cardiology 182 (2015) 426–430save statistical power and reachmeaningful conclusion. However, when
available, blood concentrations of these biomarkers were conﬁrmed to
be signiﬁcantly increased in both worsening and de novo HF patients.
The reasons for lower baseline use of beta-blockers and ACE inhibitor
were unknown. Also, LV ejection fraction was the sole robust echocar-
diographic measurement available in all patients. As a result, the rela-
tionships between diastolic function and LV ﬁlling pressure with heart
rate categories have not been evaluated.
5. Conclusions
Higher heart rate 24–36 h after admission for acute non-arrhythmic
HF is associated with increased risk of in-hospital mortality. Early
targeting of elevated heart rate might thus represent a complementary
therapeutic challenge in non-severely ill patients (i.e. cardiogenic
shock). Further studies are needed to conﬁrm our data and to deﬁne
the potential beneﬁcial impact of heart rate lowering interventions.
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